Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Open Access
- 1 May 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 91 (5) , 2326-2333
- https://doi.org/10.1172/jci116463
Abstract
The antiviral activity of azidothymidine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI) against HIV-1 was comparatively evaluated in PHA-stimulated PBM. The mean drug concentration which yielded 50% p24 Gag negative cultures were substantially different: 0.06, 0.2, and 6 microM for AZT, ddC, and ddI, respectively. We found that AZT was preferentially phosphorylated to its triphosphate (TP) form in PHA-PBM rather than unstimulated, resting PBM (R-PBM), producing 10- to 17-fold higher ratios of AZTTP/dTTP in PHA-PBM than in R-PBM. The phosphorylation of ddC and ddI to their TP forms was, however, much less efficient in PHA-PBM, resulting in approximately 5-fold and approximately 15-fold lower ratios of ddCTP/dCTP and ddATP/dATP, respectively, in PHA-PBM than in R-PBM. The comparative order of PHA-induced increase in cellular enzyme activities examined was: thymidine kinase > uridine kinase > deoxycytidine kinase > adenosine kinase > 5'-nucleotidase. We conclude that AZT, ddC, and ddI exert disproportionate antiviral effects depending on the activation state of the target cells, i.e., ddI and ddC exert antiviral activity more favorably in resting cells than in activated cells, while AZT preferentially protects activated cells against HIV infection. Considering that HIV-1 proviral DNA synthesis in resting lymphocytes is reportedly initiated at levels comparable with those of activated lymphocytes, the current data should have practical relevance in the design of anti-HIV chemotherapy, particularly combination chemotherapy.Keywords
This publication has 38 references indexed in Scilit:
- Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.Proceedings of the National Academy of Sciences, 1993
- Characterization of HIV Isolates Arising After Prolonged Zidovudine TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 1992
- Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.1992
- Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivityBiochemical Pharmacology, 1986
- Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virusVirology, 1981
- METABOLISM AND CHEMOTHERAPEUTIC ACTIVITY OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE AGAINST MURINE LEUKEMIA-L1210 AND EVIDENCE FOR ITS PHOSPHORYLATION BY DEOXYCYTIDINE KINASE1980
- Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNACell, 1977
- Human deoxycytidine kinase purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patientsBiochimica et Biophysica Acta (BBA) - Enzymology, 1977
- Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization.Journal of Biological Chemistry, 1976
- The deoxyribonucleoside 5′-triphosphate (dATP and dTTP) pool in phytohemagglutinin-stimulated and non-stimulated human lymphocytesExperimental Cell Research, 1973